Huang Lab Discovers a Novel Therapeutic Strategy for Advanced Prostate Cancer

 prostate cancer data

Jiaoti Huang, MD PhD and collaborators have published a paper in Science Translational Medicine in which they demonstrate that the currently used hormonal therapy for prostate cancer targets the majority luminal type cancer cells but leaves the minor neuroendocrine cell population untouched, which may be an important mechanism for the eventual therapy resistance and disease progression. They demonstrate that a new strategy targeting the two tumor cell populations simultaneously may achieve better outcome for the patients.

This story was featured in in  a WRAL TechWire Story.

See the full paper here: